Background--Cardiac c-Kit+ cells isolated from cardiac explant-derived cells modestly improve cardiac functions after myocardial infarction; however, their full potential has not yet been realized. For instance, the majority of potential candidates for cell therapy suffer from chronic heart failure (CHF), and it is unclear how this disease affects the explant-derived progenitor cells. Therefore, the objective of this study was to determine the effect of CHF on the number and phenotype of cardiac explant c-Kit+ progenitors and elucidate mechanisms of their regulation.
M
any adult tissues contain a rare population of multipotent progenitor cells, and mature cardiac tissues are no exception. These cardiac lineage-restricted progenitors maintain cardiac tissue homeostasis after injury. [1] [2] [3] [4] [5] Several potentially overlapping populations of endogenous cardiac progenitor cells have been identified to date on the basis of antigen expression (c-Kit, Sca1, Isl1) or function (Hoechst efflux). 1, 3, 6, 7 In addition, c-Kit+ cells have been isolated from cells spontaneously migrating from cardiac tissue cultured as "explants." 4, 5, 8, 9 The origin of explant-derived c-Kit+ cells remains unclear; however, studies suggested that these cells may derive through dedifferentiation of cardiomyocytes and/ or epicardial cells. 10, 11 If the regenerative power of these cells can be harnessed, they may serve as ideal candidates for cardiac cell therapy; however, the majority of patients who are candidates for cell therapy suffer from chronic heart failure, which may have a great impact on cardiac resident progenitor cells. Cardiac explant-derived cells including c-Kit+ cells are currently being used in clinical trials such as CADUCEUS 12 and SCIPIO. 13 For these clinical trials, autologous cardiac stem cells are used to treat heart diseases, including ischemic heart failure. Only a limited amount of heart tissue can be obtained to generate autologous explant-derived cells, whereas current transplantation protocols require a substantial amount of cells (millions). Therefore, optimizing in vitro cell expansion to maximize the amount of the cells of interest is one of the key factors of stem cell therapies. It was previously reported that both resident and explant--derived c-Kit+ cells can be expanded from pathological hearts. [14] [15] [16] Studies showed that cardiovascular diseases such as ischemic cardiomyopathy and diabetes are associated with an increase in p16(INK4a)-p53-positive stem cell senescence, telomere shortening, and a decline in functionally competent cardiac stem cells. 15, 17, 18 Here, we aimed to study the effects of congestive heart failure on the number and phenotype of cardiac explant-derived c-Kit+ progenitors and to elucidate the mechanism of their regulation. We have previously shown that the epithelial/endothelial to mesenchymal transition (EMT) played a significant role in explant-derived c-Kit+ cell regulation. 19 The EMT reflects epithelial cell plasticity and is defined by phenotypical and functional changes that are reminiscent of mesenchymal cells. 20 Previous studies showed that the EMT program is redeployed in a heart after myocardial infarction (MI). 21 Furthermore, myocardial fibrosis, a major consequence of adult heart ischemic injury, is partially mediated by the activation of epicardial and endothelial cells via EMT. 22 Transforming growth factor-b (TGF-b), a major EMT inducer, is stably upregulated within the heart after MI and plays a key role in scar formation and cardiac fibrosis. [23] [24] [25] TGF-b family proteins mainly transduce their signal to the nucleus through TGF-b serine/threonine receptors and downstream effector Smad proteins. [26] [27] [28] [29] Both canonical (Smads-dependent) and noncanonical (Smads-independent) signaling pathways could be activated via TGF-b type I receptor (TGF-b-R1). 30 For this study, we have selected animals that developed chronic heart failure (CHF) condition 6 weeks after MI. Here, we generated explant-derived cells (EDCs) from the atria of CHF-developed infarcted rats and sham-operated control rats. We tested whether the CHF milieu affects EDC composition and the c-Kit+ cell phenotype and describe the effects of TGF-b signaling modulations on c-Kit+ cells generated from sham and CHF atrial explants.
Methods

Myocardial Infarction
Animal studies were performed in accordance with federal laws and regulations, international accreditation standards (AAALAC No 1115), and institutional policies including approval by the Institutional Animal Care and Use Committee of Banner Sun Health Research Institute (IACUC protocol #10-02). Two-month-old Sprague Dawley rats (Harlan Laboratories) were anesthetized using a cocktail of ketamine, xylazine, and acepromazine (50, 15 , and 2 mg/kg, respectively). The animals were prepared using aseptic methods, intubated (14G angiocatheter), and ventilated before a left thoracotomy exposing the heart. The heart was expressed, and the left anterior descending coronary artery was ligated using a 5-0 TiCron suture as per standard protocols. The lungs were briefly hyperinflated, the chest was closed using 2-0 silk, and the rodents were allowed to recover with a pain management regiment of buprenorphine. Sham-operated animals underwent the same surgical procedure excluding left anterior descending coronary artery occlusion.
Cardiac Function Measurements
Hemodynamic statistics were collected 6 weeks post-MI using a pressure-volume catheter (Millar Instruments) inserted into the right carotid artery and advanced into the left ventricle. The animals were systemically anesthetized with Inactin (125 mg/kg) and intubated, and the steady-state measurements were collected prior to ventilation. The data were analyzed using PVAN 3.6. software (Millar Instruments).
Selection of CHF Animals
CHF animals were selected on the basis of left ventricle end-diastolic pressure measurement ≥20 mm Hg and scar size ≥30% of left ventricle. 31, 32 Approximately 35% of infarcted animals were classified as CHF and utilized in the following experiments; non-CHF animals were excluded from this study. Atrial tissues were collected 6 weeks after MI from sham-operated (n=10) and CHF (n=10) animals.
Heart Sections Processing and Staining
Heart tissue was embedded in tissue-freezing media (Triangle Biomedical Science) snap-frozen in liquid nitrogen, and sectioned in the coronal plane using a Leica CM1900 cryostat (Leica Microsystems, Bannockburn, IL). Coronal tissue sections (thickness of 5 to 7 lm) were mounted on positively charged glass slides and fixed/permeabilized in a 1:1 mixture of acetone/100% ethanol. For immunofluorescent staining, fixed tissue sections were blocked with 3% BSA in PBS and incubated with primary antibodies against vimentin (Abcam). Specific staining was visualized using corresponding secondary antibodies conjugated with Alexa 568 (Molecular Probes). Nuclei were stained with 4′,6-diamidino-2-phenylindole (Invitrogen).
Scar Size Assessment
Heart sections were prepared as described above and stained with Masson's Trichrome kit (Sigma-Aldrich) according to the manufacturer's protocol. Transmitted light images of heart sections were processed using DP2-BSW software (Olympus Corp). Scar percentage was calculated as a ratio of collagen-enriched scar area (blue staining) to the whole left ventricle area.
Cell Culture
Cardiac explant outgrowth was generated as previously described. 4, 19, 33 
TGF-b1 ELISA
To assess the amount of TGF-b1 released by explant-derived cells, 0.2910 6 cells were cultured for 4 or 10 days, and conditioned media were collected. Cell-culture medium prior to adding cells was also collected to assess baseline levels of TGF-b1. TGF-b1 levels were measured using a commercially available TGF-b1 ELISA kit (R&D Systems) according to the manufacturer's instructions. After conditioned medium was collected, total protein was extracted from cells using RIPA buffer (Thermo Scientific), and the protein amount was determined by a BCA Protein Assay kit (Thermo Scientific). TGF-b1 amounts were normalized to total protein amount.
Western Blotting
Cells were lysed in RIPA buffer (Thermo Scientific) containing Halt Phosphatase and Proteinase inhibitor cocktail (Thermo Scientific) according to the manufacturer's protocol. Protein concentration was determined using a BCA Protein Assay kit (Thermo Scientific). An equal amount of protein (50 lg) was loaded in each well of 4% to 12% bis-tris gels gel (Life Sciences) and subjected to electrophoresis. Proteins were transferred to a PVDF membrane (Millipore) and then blocked with 5% nonfat dry milk in Tris-buffered saline followed by overnight incubation with primary antibodies at 4°C. Antibodies against p-Smad2/3, Smad2/3 (Cell Signaling), and Nanog (Millipore) were used. Blots were probed with an anti-b-actin (Sigma Aldrich) antibody as a loading control. Membranes were washed in Tris-buffered saline containing 0.05% Tween 20. Corresponding horseradish peroxidaseconjugated anti-rabbit or anti-mouse IgG (Invitrogen) was used as secondary antibodies. Immunoreactive proteins were detected by chemiluminescence (Thermo Scientific). Band intensity was determined using FluorChem 8900 software (Alpha Innotech Corp).
Flow Cytometry
Cells were fixed in 70% ethanol and labeled with the following antibodies: c-Kit (Santa-Cruz Biotechnology), vimentin and smooth muscle actin (Abcam), and CD90 (BD Biosciences). Cells were treated with secondary antibodies corresponding to either anti-rabbit or anti-mouse IgG conjugated with Alexa 488, phycoerythrin (PE), or PE-Cy5.5 (Life Technologies). Direct labeling with FITC-conjugated CD34 and PE-Cy5.5 conjugated CD45 (BD Biosciences) antibodies was used to exclude bone marrow and hematopoietic cells. Freshly isolated bone marrow cells were used as positive controls for CD34 and CD45 labeling. For a negative control, cells were labeled with isotype IgG instead of primary antibody. Cell events were detected using a FACS Calibur flow cytometer equipped with an argon laser (BD Biosciences). Data were analyzed using CellQuest software (BD Biosciences).
To estimate the percentage of proliferating cells, cells were labeled with anti Ki67 antibody (Abcam) following by Alexa 488-conjugated IgG. Cells' replication state was evaluated by labeling DNA with 10 lg/mL propidium iodide (PI). G0/G1, S-phase, and G2/M were determined by setting markers for PI fluorescence using a BD Biosciences FACSCalibur with CellQuest software. 
Imaging
Images were captured at room temperature using an Olympus IX-51 epifluorescence microscope equipped with a DP72 device camera. Excitation/emission maximum filters of 490/ 520, 570/595, and 355/465 nm, were used for image acquisition. Images were processed using DP2-BSW software (Olympus Corp). Acquisition settings were held constant within each experiment.
Statistics
Results are reported as meanAESE and median and range. The nonparametric Wilcoxon rank sum test was used to compare the differences among the sham and CHF groups. The impact of TGF-b inhibitors was evaluated with the use of 1-way ANOVA. Two-way ANOVA was used to determine the interaction between disease (eg, CHF) and treatment (eg, TGF-b
). Statistical analysis was conducted using SigmaStat 3.5 software. A value of P<0.05 was considered statistically significant.
Results
CHF Is Associated With Atrial Fibrosis
Myocardial infarction was created by a permanent occlusion of the left anterior descending coronary artery. Sham-operated animals underwent the same surgical procedure excluding left anterior descending coronary artery occlusion. Six weeks after MI, rats exhibiting heart failure were selected on the basis of cardiac function measurement (Table) and histological scar evaluation ( Figure 1A) . Specifically, animals with left ventricle end-diastolic pressure ≥20 mm Hg and scar size ≥30% of the left ventricle were selected for this study and designated as CHF rats. 31, 32 Approximately 35% of infarcted animals were classified as CHF and were used in the following experiments; non-CHF animals were excluded from this study. Consistent with previous work, 34 we showed that CHF is associated with atrial hypertrophy and fibrosis. Atrial fibrosis was indicated by an increase in both collagen deposition ( Figure 1B ) and number of vimentin-positive fibroblasts
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( Figure 1C ).
CHF Alters EDC Composition
We and others have previously demonstrated that cardiac explants generate several types of cells including fibroblasts and c-Kit+ progenitors. 8, 19, 33 Cardiac explants produce EDCs of 2 morphologically distinct types: attached cells and round phase-bright cells. Attached cells were identified as differentiated fibroblasts, whereas round-phase bright cells were shown to exhibit stem cell properties. 8, 36 Because CHF modified the cardiac atrial structure ( Figure 1B and 1C) , we speculated that CHF EDC composition varies from sham EDC composition. EDCs were generated from 6-week CHF and sham animals and were characterized by flow cytometry.
Compared with sham controls, we found that CHF EDCs comprised a higher number of vimentin-positive fibroblasts Therefore, we speculated that in explant culture, a high level of TGF-b secondary to the CHF condition might affect a phenotype of CHF-derived c-Kit+ progenitors.
It was previously reported that cardiac diseases may negatively affect cardiac progenitor cell properties. 15 Here, we compared phenotypes of c-Kit+ progenitors isolated from sham and CHF EDCs. c-Kit+ cells were negative for CD34 and CD45, excluding hematopoietic origin of these cells ( Figure  S1 ). Because TGF-b is an EMT inducer, c-Kit+ cells were analyzed for EMT-related and pluripotency gene expression ( Figure 1G ). EMT is typically characterized by upregulation of the epithelial phenotype suppressor Snail and SMA and downregulation of E-cadherin. 40 Expression of Snail was 2.5-fold higher in CHF-derived c-Kit+ cells compared with shams. In contrast, the expression of the epithelial marker E-cadherin, which is negatively regulated by Snail, was 3-fold lower in CHF-derived c-Kit+ cells. Also, we measured expression of Nanog and Sox2, key transcription factors regulating self-renewal in stem cells. 39, 40 The expression of Sox2 was 4.5-fold lower and that of Nanog was 4.9-fold lower in CHF-derived c-Kit+ cells compared with sham. Taken together, the upregulation of Snail and downregulation of E-cadherin and pluripotency genes suggest EMT-like differentiation of CHF-derived c-Kit+ cells ( Figure 1G ). In addition, we observed 2. suppressed E-cadherin and Sox2 expression 2.5-and 2-fold, respectively, indicative of EMT-like transformation ( Figure 2B) . Thus, the TGF-b-induced phenotype of sham c-Kit+ cells is similar to the phenotype of untreated CHF c-Kit+ cells ( Figure  S2 ). In contrast, CHF-derived c-Kit+ cells were less responsive to TGF-b treatment; no significant differences in the expression .001, CHF vs sham. CHF indicates chronic heart failure; DAPI, 4′,6-diamidino-2-phenylindole; E-cadh, E-cadherin; EDCs, explant-derived cells; EMT, epithelial-tomesenchymal transition; MI, myocardial infarction; qPCR, quantitative polymerase chain reaction; TGF-b1, transforming growth factor-b1. of Pai1, Snail, and SMA were detected in CHF after the treatment; however, E-cadherin, Nanog, and Sox2 expression was suppressed at least 2-fold each ( Figure 2B ). Next, we tested if TGF-b signaling in c-Kit+ cells is transduced via canonical Smad signaling. c-Kit+ cells were treated with TGF-b in the presence of TGFb-R1 blocker SB or Smad3 phosphorylation blocker SIS. Expression of Pai1 was used as a readout for TGF-b signaling. 42 We found that either SB or SIS abolished 
TGF-b Inhibition in c-Kit+ Cells Diminished EMT Markers and Enhanced Pluripotency Marker Expression
TGF-b Inhibitors Increased c-Kit+ Cell Yield From Sham and CHF Explants
We previously demonstrated that cardiac explant-derived cells undergo EMT in culture resulting in a time-dependent increase in fibroblast number. Therefore, in the current study we speculated that the addition of TGF-b inhibitors in the explant culture medium can attenuate this process and improve explant-derived progenitor cell yield. Explant outgrowths were generated in the presence of the TGF-b inhibitors SB or SIS, and EDCs were analyzed by FACS. After 21 days in culture, no differences were detected in the apoptotic markers activated caspase 3 and annexin V ( Figure S5A through S5C) . Also, no differences were detected in cell proliferation and cell-cycle status, as was demonstrated by Ki67 and propidium iodide staining ( Figure S5D through S5G) . Therefore, we concluded that TGF-b inhibitors had no effect on cell growth. After 21 days in culture, we observed a higher number of small, round phase-bright cell clusters when explants were cultured in the presence of SB and, to a lesser extent, in the presence of SIS compared with controls ( Figure 5A ). In addition, when generated in the presence of inhibitors, EDCs were smaller in size and appeared tightly connected, similar to cobblestone epicardial cells. Flow cytometry results demonstrated that TGF-b inhibitors significantly decreased the percentage of vimentin-positive fibroblasts in both sham and CHF-derived EDCs (55% and 35% for SB and SIS, respectively in sham EDCs; 42% and 34% in CHF EDCs). In CHF EDCs, the number of SMA-positive myofibroblasts was reduced by 63.3% and 62.8% when generated in the presence of SB and SIS, respectively. In addition, SIS reduced the number of CD90-positive cells by 52.4% and 53%, in sham and CHF EDCs, respectively ( Figure 5B ). In contrast, SB treatment increased the number of c-Kit+ cells by 36.6% and 75% in sham and CHF EDCs, respectively, whereas SIS treatment resulted in a 52% increase in the percentage of c-Kit+ cells in sham EDCs but had no effect on CHF EDCs ( Figure 5B ). Our data showed no statistically significant interaction between CHF and treatments (eg, SB or SIS).
In summary, our results demonstrated that TGF-b signaling inhibition improves yield and function of c-Kit+ cells from sham and CHF cardiac explants.
Discussion
The current study was designed to determine if heart failure affects the yield and phenotype of atrial explant-derived c-Kit+ progenitors and to elucidate mechanisms of their cellular regulation. We showed that CHF explants produce more fibroblasts and fewer c-Kit+ progenitors. We also found that sham c-Kit+ cells are more susceptible to TGF-b signaling modulation than are CHFs; TGF-b signaling inhibition increased c-Kit+ cell yield, downregulated EMT markers, augmented Nanog expression, and stimulated cardiomyogenic potential in both sham and CHF c-Kit+ cells, but with a much higher impact in shams.
The low c-Kit+ cell yield from CHF explants could be because of several factors associated with the CHF condition. First, consistent with previous reports, 34 we found that CHF causes atrial fibrosis, and therefore, CHF explants can generate more fibroblasts. Second, post-MI cardiac resident c-Kit+ cell depletion can contribute to the low progenitor yield. Finally, during explant culturing, other type of cells, such as cardiomyocytes and epicardial cells, can contribute to the c-Kit+ cell pool via dedifferentiation, 10, 11 and therefore, a low number of CHF explant-derived c-Kit+ cells may reflect abnormality in the dedifferentiation mechanisms because of the CHF condition. Previously, it was reported that EMT plays a role in the generation of stem cells. [44] [45] [46] Our group have recently shown that in explant-derived cells c-Kit+ progenitors undergo EMT in culture. 19 "Abnormal" EMT in response to injury was described in various organs including the heart. 21 Generally, pathological EMT is involved in organ degeneration processes such a fibrosis. 20, 40 The end result of this "aggravated" form of EMT is formation of terminally differentiated fibroblasts or myofibroblasts producing extracellular matrix proteins. 20, 22 Recent studies demonstrated that up to 75% of myofibroblasts in fibrotic hearts are EMT derived. 47 However, depending on cell type and state of differentiation, EMT does not necessarily generate fibroblasts as an end product. For example, several lines of evidence demonstrated that EMT can generate stem-like cells. [44] [45] [46] Also, during heart development, primitive cardiac progenitors undergo multiple rounds of EMT without losing the stemness. 40 Explant-derived c-Kit+ cells exhibit many features of mesenchymal stem cells and appear to be in a fine balance between 2 fates, mesenchymal stem cells and myofibroblasts. 48 It is unclear which factors regulate the molecular switch between fibroblast-and stem cell-producing EMTs because at the cellular level both processes are controlled by similar signaling mechanisms. 40 EMT is widely regulated by signals from the extracellular environment. Thus, a sustained post-MI TGF-b elevation was shown to play a central role in cardiac fibrosis by inducing abnormal EMT. 24, 25, 49 In nonfractionated EDC cultures, c-Kit+ cells coexist with TGF-b-releasing fibroblasts, and compared with sham, CHF c-Kit+ cells are continuously exposed to significantly higher TGF-b in an amount sufficient to tilt the cell fate balance toward myofibroblasts. 50 Therefore, we 51 We also found that, although both studied inhibitors downregulated EMT markers and stimulated in vitro cardiac differentiation, TGF-b-R1 inhibition is more efficient in improving CHF c-Kit+ cell yield. This finding indicates that the TGF-b signal in c-Kit+ cells is not entirely transduced via Smad 2/3. Non-Smad signaling including RhoA, Rac, MAPK, and PI3/Akt kinase may contribute to CHF c-Kit+ cell regulation. 52 One potential limitation of this study is a relatively small sample size. Nevertheless, we were able to detect many differences between the sham and CHF groups as well as the effects of treatments.
In conclusion, this study has described TGF-b-dependent phenotypical differences between sham-and CHF explant--derived c-Kit+ cells and elucidated the TGF-b signaling role in c-Kit+ cell regulation. Our findings are important in optimizing the scale-up production and enhancing the efficacy of c-Kit+ cells needed for clinical application.
